Juno Pharmaceuticals importing six-months’ worth of medication as supply drops to near-zero TORONTO–(BUSINESS WIRE)–Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced that it has received approval from Health Canada to import Eptifibatide solution for infusion and injection (“Eptifibatide”) pursuant to Health Canada’s exceptional importation and sale guidelines. Juno has procured for immediate release … [Read more…]

New York City-based Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, continues to grow outside the United States NEW YORK–(BUSINESS WIRE)–#AI–Massive Bio, which uses artificial intelligence and concierge service to match cancer patients to oncology clinical trials regardless of their location or financial circumstances, continues its expansion beyond the United … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with … [Read more…]

PARIS & NEW YORK–(BUSINESS WIRE)–Inato, the leading technology platform enabling access to inclusive clinical trials, today announced the close of $20 million in Series A2 funding from existing and new investors. The fundraise includes return and lead investor Cathay Innovation, return investor Obvious Ventures, as well as new investors La Maison and Top Harvest Capital. … [Read more…]

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Aural Analytics, Inc., a leader in clinical-grade speech analytics, today announced that its Speech Vitals – ALS technology has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA). Speech Vitals – ALS is a software application used in the collection and analysis of speech recordings to assist … [Read more…]

In honour of moms coast-to-coast, Canadians can now register and raise funds for breast cancer research with every walk, step and move from April 14 to May 14 TORONTO–(BUSINESS WIRE)–Breast Cancer Canada, a national charity dedicated to saving lives through breast cancer research, today announced their spring fundraising campaign, Walk-a-Thon to Mother’s Day. This year, … [Read more…]

LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in a virtual fireside chat at Guggenheim’s Genomic Medicines and Rare Disease Days on Tuesday April 4th at 2:10 … [Read more…]

Former translational medicine head at Cyclerion Therapeutics to lead Lucy Therapeutics’ scientific development efforts WALTHAM, Mass.–(BUSINESS WIRE)–Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, as Chief Scientific Officer. For more … [Read more…]

The Arrangement Will Introduce New Leasing Options to Applied UV’s Customers for Financial Flexibility MOUNT VERNON, N.Y.MOUNT VERNON, N.Y.–(BUSINESS WIRE)–Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a leading provider of best in class suite of proprietary, patented, scientific and clinically proven, surface and air disinfection technologies (fixed, mobile and HVAC), LED lighting … [Read more…]

Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis used high statistical threshold and resulted in independent Data Monitoring Committee (DMC) recommending trial continue to final survival events, projected to occur in the first half of … [Read more…]